Journal article icon

Journal article

A safety evaluation of an extrafine aerosol of beclomethasone dipropionate in 6161 patients using the UK SAMM guidelines

Abstract:

Beclomethasone dipropionate (BDP) is an established inhaled therapy for the management of asthma. BDP is commonly delivered via a pressurized metered-dose inhaler (MDI) using a chlorofluorocarbon (CFC) propellant system. A new extrafine aerosol of BDP (QVAR, 3M Pharmaceuticals) has been developed which uses hydrofluoroalkane-134a (HFA) as its propellant. This study, conforming to the UK Safety Assessment of Marketed Medicines (SAMM) guidelines, evaluates the long-term tolerability of QVAR in ...

Expand abstract

Actions


Access Document


Authors


Holmes, WF More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Population Health
Journal:
International Journal of Pharmaceutical Medicine
Volume:
16
Issue:
4
Pages:
173-178
Publication date:
2002-08-05
DOI:
ISSN:
1364-9027
URN:
uuid:d8679614-f954-4d91-9f0b-67c376485c3a
Source identifiers:
162351
Local pid:
pubs:162351

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP